Combination treatment for advanced lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two drugs, glofitamab and selinexor, for patients with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two previous treatments. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have DLBCL that is CD20-positive (a protein on the cancer cells) and has returned or not responded to at least two prior treatments.
- You have measurable disease (a tumor that can be seen on scans).
- You are able to perform daily activities (ECOG score 0-2) and have adequate organ function.
- You have not been treated with certain similar drugs (bispecific antibodies or XPO1 inhibitors) in the past.
- You do not have active infections (like HIV, hepatitis B, or hepatitis C) or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This study tests a new combination of drugs for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The combination includes an experimental drug (EZH2i), an immunotherapy (glofitamab), and chemotherapy (GemOx), all given together to see if it is safe and effective.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This study tests whether adding a drug called selinexor to a standard chemo-immunotherapy combination (called R-GDP) can help people whose large B-cell lymphoma has a TP53 gene change and has not responded to earlier treatment. The goal is to see if this combination helps control the lymphoma.
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.